Conclusions
In our discipline, a huge amount of omics research has been employed during recent years that needs to be analyzed in depth. Allergic diseases are a group of complex and heterogeneous diseases. Specific, sensitive and reliable (point-of-care) biomarkers are critical for selecting the proper treatment for the proper patient and enabling precision medicine. Precision endotyping is linking pathobiological mechanisms with visible properties via specific biomarkers. It is expected to be translated into pathway-specific diagnostic tests and opens a pathway to accurate disease classification and individualized targeted treatment options. We are expecting to change the diagnostic and therapeutic landscape in our specialty as well as of all medical disciplines. However, endotype-driven treatment still needs to face multiple challenges before its implementation in daily practice in allergic diseases and asthma. Most of the disease endotyping research is conducted in severe forms of allergic diseases nowadays. Over the past few years, the biomarker discovery field has gained great advances, which facilitates the identification of novel methods for disease diagnosis and therapy. With these fast-growing efforts, we can imagine that in the near future, we will be able to find better ways to treat allergic diseases, with a therapeutic approach targeted to the individual patient.